Abstract: The present invention provides a low-molecular inhibitor of GIP functions and, further, an agent for preventing/ameliorating obesity based on inhibition of GIP functions, which comprises, as an active ingredient, a compound represented by the following general formula (I): (wherein R1 represents hydrogen, halogen, a nitro group or a cyano group, R2 and R3 each represent hydrogen or halogen, hydrogen or a methoxy group, or both R2 and R3 may form an optionally substituted benzene or pyrrole ring, and A represents nitrogen or C—R4 whereupon R4 represents hydrogen, an optionally substituted C1 to C6 alkyl group, —OR7, —NR8R9, —NHCO—R10 or —SO2—R11 or may, together with R3, form an optionally substituted benzene or pyrrole ring, R7, R8 and R9 each represent hydrogen or an optionally substituted C1 to C6 alkyl group, R10 represents a C1 to C6 alkyl group or the like, and R1 represents an optionally substituted morpholyl group or the like) or a pharmaceutically acceptable salt thereof.

Abstract: Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.

Abstract: Compounds of formula A and formula B: and their pharmaceutically acceptable salts, compositions comprising them, methods for their use, and their use in the preparation of medicaments. The compounds are antagonists of MCP-1 function, and are useful in the prevention and treatment of chronic or acute inflammatory or autoimmune diseases, such as multiple sclerosis, and in the prevention and treatment of allergic hypersensitivity disorders.

Abstract: Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.

Abstract: The subject is to manufacture molding with core efficiently and at one time from molding material such as powder granule. To this end, a method for manufacturing molding with core was invented, which method uses compression molding means, that comprise a die, and upper and lower punches, where at least the upper punch, preferably both the upper and lower punches, have a double structure consisting of a central punch and an outer punch surrounding the outer periphery of the central punch, both the central punch and the outer punch being capable of performing sliding motions as well as compressing operations. This method includes steps of separate supplying of molding materials for core and molding material for outer layer, a compression molding step of the molding material for core and/or the molding material for outer layer, and a compression molding step of the whole molding with core. The invention also provides a rotary compression molding machine, used for execution of the method.

Abstract: The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.

Abstract: The invention relates to a polystyrene sulfonate-containing gel preparation for therapy of hyperpotassemia, wherein the particle size of polystyrene sulfonate is controlled within the range of at least 5-100 &mgr;m, the viscosity of its solution before gelation is adjusted depending on the particle size by adding a thickening agent, and the polystyrene sulfonate particles after gelation is uniformly dispersed therein. More preferably, a water-displacing agent is contained, whereby the amount of water in the preparation is reduced. This gel preparation does not cause a sense of foreign matter or a sense of roughness in the oral cavity upon ingestion and intake, thus making it unnecessary to drink water for ingestion, and further its water content is low, so that control of water intake is made easy, even in the case of a patient with renal insufficiency who is subjecting to restriction in intake of water to significant improve the quality of life of the patient.

Abstract: Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.

Abstract: The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.

Abstract: A multi-layered film preparation is disclosed having a drug-containing layer which contains at least one water-soluble high molecular weight compound as a main base material, a layer which is made difficult to dissolve in water and positioned at one side of the drug-containing layer and a powdery adhesive compound positioned at the other side of the drug-containing layer.

Abstract: A pharmaceutical composition is disclosed comprising a fat emulsion containing microspheres and having its electric charge adjusted to a negative value and a biologically active substance selected from the group consisting of a basic peptide and a basic protein, which biologically active substance is adsorbed to the microspheres in the fat emulsion. An acidic phospholipid, a fatty acid, a bilic acid and a salt of such substances is preferred as an agent for adjusting the electric charge of the fat emulsion. Motilin derivatives, vasoactive intestinal polypeptide derivatives and calcitonin are preferred biologically active substances.

Abstract: A potentiator for interferon and an antiviral activity-potentiating composition containing interferon and its potentiator are provided. The potentiator is a mixture of flavin adenine dinucleotide (FAD) and porcine liver extract.

Abstract: A maillard reaction inhibitor comprising, as the principal component, an eight-structural polymer of 3-oxygermylpropionic acid represented by the following stereostructure (I): ##STR1## wherein R represents --CH.sub.2 CH.sub.2 COOH, and m is a weight average polymerization degree calculated on the basis of the weight average molecular weight of propagermanium propyl ester and is 137.+-.84 (137 on average with a standard deviation of .+-.3.sigma.); and having the following minimum constitutional unit:(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOHand the following empirical formula:C.sub.6 H.sub.10 Ge.sub.2 O.sub.7,a method for inhibiting the Maillard reaction, and a method for preventing and treating diseases caused by Maillard reaction such as diabetes and concurrent diseases thereof.

Abstract: Wart of human being is prevented or cured by administration of a pharmaceutical composition containing an eight structural polymer of 2-oxygermylpropionic acid having an empirical formula of C.sub.6 H.sub.10 Ge.sub.2 O.sub.7, a minimum constitutional unit of (O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH and the following stereostructure: ##STR1## wherein R stands for --CH.sub.2 CH.sub.2 COOH and m is an integer of 137.+-.84.

Abstract: There are disclosed a 1-azabicyclo[3.3.0]octan derivative of the formula ##STR1## wherein n is an integer of 1-5; and Ar is an aromatic residue. a pharmacologically acceptable salt of the compound, a process for the preparation of the compound and salt as well as use thereof as hypermotility agents.

Abstract: The invention provides a polypeptide of calcitonin analogue and use thereof. The polypeptide has such an amino acid sequence that proline-amide residue (Pro-NH.sub.2) at C-terminal of native eel calcitonin is substituted to a homoserine amide residue (Hse.multidot.NH.sub.2).

Abstract: A novel, eight structural polymer of 2-oxygermylpropionic acid having an empirical formula of C.sub.6 H.sub.10 Ge.sub.2 O.sub.7, a minimum constitutional unit of (O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH and the following stereostructure: ##STR1## wherein R stands for --CH.sub.2 CH.sub.2 COOH and m is an integer of 137.+-.84. A pharmaceutical composition containing the novel polymer is useful for preventing symptoms of an immune disease such as hepatitis or for curing such a disease.

Abstract: There is disclosed a compound shown by a formula of ##STR1## wherein R.sub.1 is a hydrogen atom alkyl group having 1-4 carbon atoms or acyl group having 1-4 carbon atoms: R.sub.2 and R.sub.3 are a hydrogen atom, alkyl group having 1-4 carbon atoms, phenyl radical, halogen atom, cyano radical, acyl group having 1-4 carbon atoms, nitro radical, alkoxy group having 1 or 2 carbon atoms, or substituted or non-substituted amino group, respectively; n is an integer of 1-3; and dotted line means a possible ring, and a salt thereof. The compound and salt bind with muscarinic receptor in brain to develop a powerful actuation thereof and thus those can be used as an effective ingredient for preventing and curing senile dementias, and more particularly Alzheimer's disease.

Abstract: The modified polypeptide compound of the present invention is represented by the following general formula ((SEQ ID NO: 2)-X):His-Ser-Asp-Ala-Val-Phe-Thr-Gly-Asn-Tyr-Thr-Lys-Leu-Arg-Lys-Gln-Leu-Ala-Ala -Lys-Lys-Tyr-Leu-R.sup.1 -Lys-Ala-Leu-R.sup.2 -Hse-Xwherein R.sup.1 represents an Asn, Lys or Gln residue, R.sup.2 represents a Lys or Arg residue, Hse represents a homoserine residue, and X represents NHR.sup.3 or NR.sup.4 R.sup.5, wherein R.sup.3 represents a hydrocarbon residue having 18 or less carbon atoms or a polyalkylamine having 2 or more amino groups in its molecule, or R.sup.4 and R.sup.5 represent hydrocarbon residues, provided that the total carbon number of R.sup.4 and R.sup.5 is 18 or less. This modified polypeptide compound has a strong activity as a smooth muscle relaxant, and has excellent stability and prolonged duration of action. These characteristics make it suitable as an active ingredient in a drug for preventing and treating bronchial asthma and impotence.

Abstract: There are disclosed a benzopyrancarboxamide derivative of the formula ##STR1## wherein R.sup.1 is hydrogen atom or a lower alkyl group; R.sup.2 is hydrogen atom, a lower alkyl group, halogen atom, an amino radical or an acylamino group; R.sup.3 is hydrogen atom, a lower alkyl group, a lower alkoxy group or halogen atom; dotted line is a possible double bond; and n is an integer of 1-5,and a pharmacologically acceptable salt of the compound, a process for the preparation of the compound and salt as well as use thereof.